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Objective. Oxidative stress and oxidized high-
density lipoprotein (HDL) are implicated as risk factors
for cardiovascular disease (CVD) in systemic lupus
erythematosus (SLE). Yet, how HDL is oxidized and
rendered dysfunctional in SLE remains unclear. Neu-
trophil extracellular traps (NETs), the levels of which
are elevated in lupus, possess oxidant-generating en-
zymes, including myeloperoxidase (MPO), NADPH ox-
idase (NOX), and nitric oxide synthase (NOS). We
hypothesized that NETs mediate HDL oxidation, im-
pairing cholesterol efflux capacity (CEC).
Methods. Plasma MPO levels and CEC activity
were examined in controls and lupus patients, and
3-chlorotyrosine (MPO specific) and 3-nitrotyrosine
(derived from reactive nitrogen species) were quantified
in human HDL. Multivariable linear models were used
to estimate and test differences between groups. HDL
was exposed to NETs from control and lupus neutro-
phils in the presence or absence of MPO, NOX, NOS
inhibitors, and chloroquine (CQ). Murine HDL oxida-
tion was quantified after NET inhibition in vivo.
Results. SLE patients displayed higher MPO lev-
els and diminished CEC compared to controls. SLE
HDL had higher 3-nitrotyrosine and 3-chlorotyrosine
content than control HDL, with site-specific oxidation
signatures on apolipoprotein A-I. Experiments with
human and murine NETs confirmed that chlorination
was mediated by MPO and NOX, and nitration by NOS
and NOX. Mice with lupus treated with the NET
inhibitor Cl-amidine displayed significantly decreased
HDL oxidation. CQ inhibited NET formation in vitro.
Conclusion. Active NOS, NOX, and MPO within
NETs significantly modify HDL, rendering the lipopro-
tein proatherogenic. Since NET formation is enhanced
in SLE, these findings support a novel role for NET-
derived lipoprotein oxidation in SLE-associated CVD
and identify additional proatherogenic roles of neutro-
phils and putative protective roles of antimalarials in
autoimmunity.
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Patients with systemic lupus erythematosus
(SLE) exhibit enhanced morbidity and mortality from
premature atherosclerotic cardiovascular disease
(CVD), which is not explained by the Framingham risk
equation (1–3). While immune dysregulation plays a
prominent role in CVD in SLE, the mechanisms remain
unclear. We proposed that altered innate immune re-
sponses play important roles in the development of
endothelial damage and plaque formation in SLE (4–7).
In addition, lipoprotein abnormalities triggered by oxi-
dative stress may promote atherogenesis in systemic
autoimmune diseases (3,8–10).
Myeloperoxidase (MPO) is a major source of
reactive oxidants within the human vasculature. Classi-
cally thought of as macrophage-derived, MPO localizes
to atherosclerotic plaques, and its activity is linked to
plaque rupture (10–12) and oxidation of high-density
lipoprotein (HDL) (8,13,14). In its native form, HDL
has vasoprotective properties due to its ability to remove
excess cholesterol from arterial wall macrophages, via
ATP-binding cassette transporter A1 (ABCA1) interac-
tions, and pleiotropic antiinflammatory and antioxidant
effects (10,15–17). When apolipoprotein A-I (Apo A-I),
the most abundant protein within HDL, becomes oxi-
dized via chlorination or nitration of tyrosine residues
(Cl-Tyr– and N-Tyr–oxidized HDL, respectively), the
lipoprotein loses vasoprotective capabilities and gains
proinflammatory activity (8,10,13,14,17,18). Patients
with chronic inflammatory diseases, including SLE and
rheumatoid arthritis (RA), have increased levels of
oxidized HDL (8,9). However, the mechanisms and
dominant cellular sources leading to HDL oxidation are
still unclear.
Phagocytes possess the machinery to oxidize
biomolecules and represent attractive candidates for
HDL oxidation. In addition to MPO, phagocytes display
NADPH oxidase (NOX) activity (19), which can lead to
superoxide anion (O2
•) and hydrogen peroxide (H2O2)
production, both of which are damaging oxidative spe-
cies. Indeed, increased NOX activity is significantly
associated with CVD (19). MPO can transform NOX-
generated H2O2 into hypochlorous acid (HOCl) if chlo-
ride is present, or generate nitrogen dioxide radical
(NO2
•), a reactive nitrogen species (RNS), if nitrite is
present, promoting both vascular damage and HDL
oxidation. Previous studies indicated associations be-
tween plasma MPO levels and CVD in the general
population, although it remains unclear if this is more
relevant to specific patient subsets (11,20). As enhanced
circulating MPO activity has been described in SLE (21),
this raises the possibility that circulating sources of MPO
play key roles in lipoprotein oxidation in lupus, as
previously observed in RA by our group (8).
The 3 isoforms of nitric oxide synthase (NOS) in
humans, endothelial cell NOS (eNOS), neuronal NOS
(nNOS), and inducible NOS (iNOS), can generate nitric
oxide (NO•). While NO• is generally vasoprotective, it
can combine with NOX-generated O2
• to produce the
RNS peroxynitrite (ONOO) or be dismutated into
H2O2, leading to HOCl or NO2
•, which are potential
oxidizers of HDL. While reports in the literature are
mixed (22,23), iNOS is the isoform most associated with
CVD risk.
The oxidation of HDL, by NOS/NOX-produced
ONOO or MPO/NOX-generated NO2
• and HOCl,
transforms the lipoprotein into a proatherogenic form
that can increase vascular damage and inflammatory
cytokine production (10,12,14,15,17,18). While the roles
of NOS, NOX, and MPO in CVD are largely associated
with macrophages and endothelial cells, these enzymes
are important for neutrophil respiratory bursts
(12,24,25).
Neutrophil extracellular traps (NETs) are extra-
cellular fibers composed of DNA, histones, and micro-
bicidal granular proteins that play important roles in
antimicrobial responses (26,27). NET formation is trig-
gered by microbes, platelets, cytokines, and immune
complexes, and is enhanced in various autoimmune
disorders including SLE (4,6,26–32). While NET forma-
tion pathways are not fully characterized, the process
appears to be dependent on MPO, NOX, and peptidyl-
arginine deiminase type 4 (PAD4) activity (26,27,32–
34). Beyond their role in innate defense mechanisms and
autoimmunity, NETs have been implicated in CVD by
promoting thrombosis and proatherogenic innate im-
mune responses (1,6,35–37). Neutrophils and NETs
have been detected in the vasculature tunica externa and
in the lumen (35,38,39). Pertinent to SLE, we identified
a subset of aberrant neutrophils in lupus peripheral
blood named low-density granulocytes (LDGs), which
are primed to form NETs with enhanced oxidant exter-
nalization (4,7). We hypothesized that NETs formed by
lupus LDGs may represent a prominent source of
extracellular NOS, NOX, and MPO, leading to
proatherogenic HDL oxidation.
PATIENTS AND METHODS
Patients. Plasma samples were collected from SLE
patients who fulfilled the American College of Rheumatology
SLE classification criteria (40). Healthy controls were re-
cruited by advertisement. The study was approved by the
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University of Michigan and NIH Institutional Review Boards.
Lupus disease activity was quantified by the SLE Disease
Activity Index (SLEDAI) (41). Pregnant or lactating women
and individuals with recent or current infections or liver
dysfunction were excluded.
Mice. NZM2328 (NZM) breeding pairs were a gift
from Dr. Chaim Jacob (University of Southern California, Los
Angeles) (5). BALB/c mice were purchased from The Jackson
Laboratory. Mice were bred and housed in a specific
pathogen–free barrier facility at the University of Michigan.
Female mice were killed at 24 weeks of age, before overt
development of renal disease. The protocol was approved by
the University of Michigan’s Committee on Use and Care of
Animals.
Plasma HDL isolation. HDL was isolated from human
and murine plasma by sequential ultracentrifugation (8). The
protein concentration was estimated with Coomassie staining
(Thermo Scientific). Samples were stored at 80°C until
analyzed.
Quantification of oxidized amino acids in plasma,
HDL, and Apo A-I peptides. Plasma proteins were precipitated
and delipidated (8); oxidized amino acids were quantified
using isotopically labeled internal standards, 13C6 tyrosine,
13C6 3-chlorotyrosine, and
13C6 3-nitrotyrosine, by liquid
chromatography-electrospray ionization tandem mass spec-
trometry (LC-ESI-MS/MS) with multiple reaction monitoring
MS/MS positive-ion acquisition mode (42).
Multiple reaction monitoring analysis of oxidized
tyrosine–containing Apo A-I peptides with LC-ESI-MS/MS.
Plasma HDL samples were delipidated and reduced with
dithitreitol (5 M; Sigma-Aldrich) before alkylation with io-
doacetamide (15 mM; Sigma-Aldrich) (8). Samples were
trypsin-digested and purified using solid-phase extraction C18
Sep-Pak columns (Waters). Isotopically labeled oxidized (ni-
trated and chlorinated) peptides and native Apo A-I peptides
were spiked into samples following trypsin digestion. Multiple
reaction monitoring analysis was performed with an Agilent
6490 Triple Quadrupole MS system equipped with an Agilent
1200 Infinity UPLC (Agilent) in positive ion mode (8).
Cholesterol efflux capacity (CEC) and MPO quantifi-
cation. CEC assay and MPO quantification were performed as
previously described (8). J774 cells were maintained in Dul-
becco’s modified Eagle’s medium (DMEM)/10% fetal bovine
serum (FBS; Life Technologies) (43). To radiolabel the cellu-
lar free cholesterol pool, cells were incubated with 1 Ci/ml
3H-cholesterol (PerkinElmer) in DMEM/1 mg/ml fatty acid–
free bovine serum albumin (BSA) and 5 g/ml Acyl-CoA:
cholesterol acyltransferase inhibitor Sandoz 58-035 (Sigma-
Aldrich) overnight. Cells were incubated with 0.5 mM 8-Br-
cAMP for 20 hours to induce ABCA1 expression, incubated
with DMEM/fatty acid–free BSA with or without 2.8% Apo
B–depleted plasma for 4 hours at 37°C, and then chilled on ice.
Medium was collected and filtered, the 3H-cholesterol content
of medium and cells was quantified, and the fraction of total
3H-cholesterol released into the medium was calculated (8).
Induction and purification of NETs and coculture
assays. Human control neutrophils and lupus LDGs were
purified from the peripheral blood (4), and murine neutrophils
were purified from the bone marrow (6). Cells were plated at
a density of 0.25  106 cells/cm2 on tissue culture plates in
RPMI 1640 without phenol red (Life Technologies) for Cl-Tyr
quantification, or in Krebs-Ringer phosphate glucose (KRPG;
Sigma-Aldrich) for N-Tyr quantification (4). Neutrophils were
cultured in the presence or absence of 20 nM phorbol myristate
acetate (PMA; Sigma-Aldrich) for 3 hours (human), or 100 nM
PMA for 5 hours (mouse) to induce NET formation (27). Since
LDGs form NETs spontaneously, they were left unstimulated.
To inhibit NET formation, 200 M Cl-amidine was added for
the full incubation (6). Since NOX and MPO are required for
NET formation but are also targets for the conditions in which
oxidation was inhibited, cells were allowed to form NETs for 1
hour before adding the following inhibitors: diphenyleneiodo-
nium (DPI), which blocks NOX activity (100 M; Tocris),
L-NG-monomethyl-L-arginine (L-NMMA), which blocks NOS
activity (200 M; Abcam), and 3-amino-1,2,4-triazole (3-AT),
which blocks MPO activity (10 mM; Sigma-Aldrich)
(26,27,32,33,44,45). Inhibitors were replenished hourly during
NET formation. NETs were isolated as previously described,
using 100 units/ml DNase I (Roche) (31). Supernatants result-
ing from the final spin contained NET-bound proteins and
DNA fragments. Control, nonoxidized HDL (50 g/ml) was
incubated with NETs in the presence or absence of L-NMMA,
3-AT, and DPI, for 30 minutes at 37°C. The relative abundance
of HDL oxidation was calculated as the fold change of each
condition relative to HDL oxidation with NET formation.
Quantification of NOS and NOX in human and mu-
rine NETs. Immunoblot analysis. To detect NOS and NOX
externalization during NET formation, digested human and
murine NETs and whole neutrophil pellets were harvested.
NET proteins were precipitated with acetone; 50 g of NET or
whole cell pellet proteins were separated on a 10% sodium
dodecyl sulfate–polyacrylamide gel electrophoresis gel. Pro-
teins were transferred onto a nitrocellulose membrane, incu-
bated in 5% BSA/Tris buffered saline/0.1% Tween 20 for 1
hour, and stained with goat anti-mouse p47 or p22 (1:200;
Santa Cruz Biotechnology), rabbit anti-eNOS or anti-iNOS
(1:100; Abcam), or anti-tubulin (negative control; 1:500)
(Sigma-Aldrich), followed by horseradish peroxidase–
conjugated rabbit anti-goat (1:1,000; Millipore) or goat anti-
rabbit (1:5,000; Jackson ImmunoResearch) secondary
antibodies. Densitometry was performed with Quantity One
(Bio-Rad).
Fluorescence microscopy. Human control neutrophils
and lupus LDGs and mouse neutrophils were seeded onto
poly-L-lysine–coated coverslips (Sigma-Aldrich) (4,6), stimu-
lated with PMA as described above, or left unstimulated (for
LDGs) before fixing in 4% paraformaldehyde and staining
with goat anti-p47 or anti-p22 (both 1:50 dilution; Santa Cruz),
or rabbit anti-iNOS or anti-eNOS (both 1:20 dilution; Abcam)
for 1 hour at 4°C, followed by staining with secondary
fluorochrome-conjugated antibodies (Jackson ImmunoRe-
search) and Hoechst 33342 (Life Technologies). Coverslips
were mounted with ProLong Gold Antifade (Life Technolo-
gies). Images were acquired on a Zeiss LSM 510 META laser
scanning confocal microscope (Carl Zeiss Microimaging) with
a 63 lens and quantified (4,6).
Effect of chloroquine (CQ) on neutrophils. Whole
blood was incubated with 250 ng/ml CQ (Sigma-Aldrich) for 2
hours before neutrophils and LDGs were purified (17). The
effect of CQ on NET formation was quantified using a Sytox
assay (Life Technologies) (31), immunofluorescence staining,
and immunoblotting. To determine the effect of CQ on MPO,
NOS, and NOX activity, 1  106 granulocytes/ml, in either
RPMI 1640 or KRPG with protease inhibitor cocktail (Roche),
2534 SMITH ET AL
were homogenized at 35,000 revolutions per minute (Omni
International) for three 10-second intervals on ice before
treatment with or without 20 nM PMA for 30 minutes, then in
the absence or presence of 250 ng/ml CQ for 30 minutes, and
finally with or without 50 g/ml HDL for 30 minutes. Samples
were frozen and analyzed for Cl-Tyr and N-Tyr oxidation.
In vivo Cl-amidine administration. PAD inhibitor
Cl-amidine was synthesized (46). Twelve-week-old female
NZM mice were administered daily subcutaneous injections of
Cl-amidine (10 mg/kg/day) or phosphate buffered saline (Life
Technologies) for 14 weeks (6). Plasma was isolated, and HDL
was purified (5).
Statistical analysis. Pearson’s correlation coefficients
were calculated for the outcomes studied and patient charac-
teristics. Multivariable linear models were used to explore
significant predictors of the outcomes of interest. The method
of best subsets with the R-squared selection criterion guided
the model selection process (8). These models were also used
to estimate and test differences between control and SLE
groups. Skewed variables were logarithm base 10 or natural log
transformed to satisfy statistical assumptions. Normally distrib-
uted variables were not transformed. P values less than 0.05
were considered significant. Analyses were conducted using
SAS V.9.2 or GraphPad Prism version 5.
RESULTS
Patient characteristics. Controls and lupus pa-
tients did not differ in demographic characteristics (Ta-
ble 1). Levels of low-density lipoprotein (LDL) were
significantly lower in patients with SLE, possibly associ-
ated with prevalent use of statins (22.5%). In SLE
patients, use of statins correlated with elevated plasma
Cl-Tyr levels, whereas antimalarial use was associated
with increased plasma N-Tyr content (Table 2). SLE
patients displayed significantly higher levels of plasma
MPO than controls (median 425.5 versus 326.7 fmoles/
ml; P  0.05). Elevated MPO levels significantly corre-
lated with an increased erythrocyte sedimentation rate
and low LDL levels. Oxidation levels did not correlate
with SLEDAI scores (Table 2).
Impaired CEC in SLE. The ability of HDL to
promote cholesterol efflux from macrophages is a metric
of HDL function and has a strong inverse association
with CVD (3,14,17). Plasma from patients with SLE
displayed significantly diminished CEC when compared
to control plasma (mean  SD 9.2  1.6% in controls
versus 7.8 1.5% in SLE patients; P 0.001) (Table 1).
These results persisted after adjustment for significant
predictors of CEC (Table 2) and support previous
indications that dysfunctional HDL present in SLE leads
to impaired CEC and may promote proatherogenic
responses (3).
Increased chlorinated and nitrated HDL in SLE.
Impaired CEC has been associated with HDL modifica-
tions such as nitration and chlorination (14,18). We
quantified levels of Cl-Tyr, a highly specific product of
MPO, and N-Tyr, a product of MPO and other RNS-
producing enzymes, in HDL isolated from SLE patients
and controls and in total plasma (8,42). SLE HDL
displayed 1.9-fold higher median levels of N-Tyr (72.3
versus 38.7 moles/mole Tyr; P 0.0057) and 120.9-fold
higher median levels of Cl-Tyr (229.8 versus 1.9 moles/
mole Tyr; P  0.0001), compared to control HDL
(Figure 1B) even after adjustment (Table 2). Because a
majority (72.5%) of the SLE patients were receiving
antimalarials (Table 1), we determined the effect of
antimalarial treatment in the study population. Adjust-
ing for antimalarial use had no significant effect on the
values in Table 1 or Table 2 (data not shown). Since
previous studies demonstrated that chlorination of ty-
rosine residue 192 (Tyr192) within the Apo A-I protein
most directly associates with impaired CEC (14), with 6
other Apo A-I tyrosine residues (Tyr18, Tyr29, Tyr100,
Tyr115, Tyr166, and Tyr236) as other potential sites of
oxidation (8,13), we determined if regiospecific nitration
and chlorination patterns occur in SLE. The highest
levels of MPO-dependent Cl-Tyr HDL oxidation in SLE
samples were observed at tyrosines 192, 115, and 18
(Figure 1C), when compared to control samples. Levels
of N-Tyr HDL oxidation were highest at tyrosines 192,
Table 1. Demographic and clinical characteristics of the healthy





Age, mean  SD years 47.5  10.9 48.2  13.5
Sex, no. (%) male 2 (10) 4 (10)
Body mass index, kg/m2 24.0 (6.6) 27.8 (12.2)
Cholesterol, mg/dl 212.0 (58.0) 150.0 (87.0)
Triglycerides, mg/dl 161.5 (89.0) 124.5 (99.0)
HDL, mg/dl 57.5 (28.0) 52.0 (18.5)
LDL, mean  SD mg/dl 128.1  29.7 92.9  39.6†
ESR, mm/hour NA 13.0 (13.0)
C-reactive protein, mg/liter NA 0.6 (0.7)
SLEDAI 0 3.0 (6.0)†
Treatment, no. (%)
Steroids 0 (0) 17 (42.5)†
Antimalarials 0 (0) 29 (72.5)†
Statins 0 (0) 9 (22.5)†
Beta-blockers 0 (0) 10 (25)†
ACE inhibitors 0 (0) 9 (22.5)†
MPO, fmoles/ml 326.7 (156.0) 425.5 (212.0)†
Cholesterol efflux capacity,
mean  SD %
9.2  1.6 7.8 1.5†
* Except where indicated otherwise, values are the median (interquar-
tile range). SLE systemic lupus erythematosus; HDL high-density
lipoprotein; LDL  low-density lipoprotein; ESR  erythrocyte
sedimentation rate; NA  not available; SLEDAI  SLE Disease
Activity Index; ACE  angiotensin-converting enzyme; MPO 
myeloperoxidase.
† P  0.05 versus healthy controls.
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Pearson correlations among all patients (n  60)
Age, years
r 0.23 0.11 0.03 0.07 0.05 0.02
P 0.08 0.39 0.83 0.61 0.71 0.89
Sex, male
r 0.21 0.05 0.21 0.14 0.08 0.04
P 0.11 0.72 0.12 0.30 0.54 0.77
BMI, kg/m2†
r 0.20 0.23 0.31‡ 0.05 0.18 0.07
P 0.13 0.08 0.02‡ 0.72 0.18 0.61
Cholesterol, mg/dl†
r 0.13 0.14 0.04 0.58‡ 0.25 0.23
P 0.33 0.31 0.77 0.01‡ 0.07 0.10
Triglycerides, mg/dl†
r 0.11 0.07 0.14 0.01 0.02 0.16
P 0.44 0.62 0.32 0.94 0.90 0.26
HDL, mg/dl†
r 0.25 0.28‡ 0.15 0.04 0.17 0.01
P 0.08 0.05‡ 0.28 0.79 0.22 0.96
LDL, mg/dl
r 0.44‡ 0.18 0.29‡ 0.12 0.46‡ 0.27
P 0.01‡ 0.22 0.04‡ 0.41 0.01‡ 0.06
Pearson correlations among SLE patients
only (n  40)
CRP, mg/liter†
r 0.05 0.18 0.17 0.11 0.24 0.16
P 0.76 0.27 0.31 0.52 0.15 0.34
ESR, mm/hour†
r 0.36‡ 0.06 0.05 0.19 0.07 0.14
P 0.02‡ 0.71 0.75 0.26 0.66 0.40
SLEDAI
r 0.14 0.08 0.15 0.06 0.15 0.05
P 0.39 0.63 0.34 0.71 0.36 0.76
Steroid use
r 0.09 0.11 0.20 0.27 0.11 0.09
P 0.59 0.51 0.22 0.09 0.49 0.57
Antimalarial use
r 0.03 0.08 0.08 0.05 0.20 0.32‡
P 0.83 0.64 0.62 0.76 0.23 0.05‡
Statin use
r 0.18 0.13 0.002 0.01 0.32‡ 0.12
P 0.26 0.42 0.99 0.95 0.05‡ 0.48
Beta-blocker use
r 0.07 0.22 0.15 0.26 0.16 0.004
P 0.66 0.17 0.36 0.11 0.32 0.98
ACE inhibitor use
r 0.06 0.16 0.09 0.12 0.01 0.06
P 0.70 0.33 0.59 0.46 0.96 0.71
Comparisons of MPO, CEC, and lipoprotein profiles
between controls and SLE patients§
Unadjusted comparison
Controls 5.7  0.1 9.2  0.3 1.4  0.4 2.5  0.4 0.4  0.3 3.4  0.2
SLE patients 6.0  0.1 7.8  0.2 5.4  0.3 4.2  0.3 3.3  0.2 5.7  0.1
P 0.0005 0.0022 0.0001 0.0003 0.0001 0.0001
Model R2 0.19 0.15 0.51 0.2 0.49 0.64
Adjusted comparison
Controls 5.8  0.1 9.2  0.3 1.5  0.4 2.6  0.3 0.3  0.3 3.3  0.2
SLE patients 6.0  0.1 8.0  0.3 5.4  0.3 4.1  0.2 3.3  0.2 5.7  0.2
P 0.0198 0.0073 0.0001 0.0002 0.0001 0.0001
Model R2 0.4 0.21 0.56 0.49 0.62 0.63
* SLE  systemic lupus erythematosus; CRP  C-reactive protein, ESR  erythrocyte sedimentation rate, SLEDAI  SLE Disease Activity Index;
ACE  angiotensin-converting enzyme.
† Natural log transformed prior to correlation calculation.
‡ Significant results (P  0.05).
§ Values are the differences in the estimated means between groups  SEM. Cholesterol efflux capacity (CEC; %) was adjusted for high-density
lipoprotein (HDL) (R2  0.08; n  50), myeloperoxidase (MPO; fmoles/ml) was adjusted for age, body mass index (BMI), and low-density
lipoprotein (LDL) (r2  0.33; n  49), HDL 3-chlorotyrosine (Cl-Tyr) was adjusted for BMI (R2  0.10; n  59), HDL 3-nitrotyrosine (N-Tyr) was
adjusted for cholesterol (R2  0.34; n  54), plasma Cl-Tyr was adjusted for LDL (R2  0.21; n  50), and plasma N-Tyr was adjusted for LDL
(R2  0.07; n  50).
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Figure 1. High-density lipoprotein (HDL) isolated from patients with systemic lupus erythematosus (SLE) is significantly oxidized and
dysfunctional. Plasma and HDL from healthy controls and SLE patients were purified. A, ATP-binding cassette transporter A1–mediated cholesterol
efflux capacity (determined in J774 cells loaded with radiolabeled 3H-cholesterol and then incubated with SLE or control apolipoprotein B [Apo
B]–depleted plasma) in controls and SLE patients. B, Reactive nitrogen species– and myeloperoxidase (MPO)–mediated 3-nitrotyrosine (N-Tyr)
levels and MPO-specific 3-chlorotyrosine (Cl-Tyr) levels in HDL from controls and SLE patients. C, Distribution of isotopically labeled nitrated or
chlorinated tyrosines. Native Apo A-I peptides were spiked into HDL samples from controls and SLE patients. Extracted ion chromatograms from
specific fragment ions were used for quantitative analysis. Data in A–C are shown as box plots. Each box represents the interquartile range (IQR).
Lines inside the boxes represent the median. Whiskers represent the highest value within the upper fence and the lowest value within the lower fence.
Circles indicate outliers (1.5 times the IQR). Data in B and C are displayed on the log10 scale. Medians (IQR) are reported on the raw scale.
  P  0.05 versus controls. D, Scatter plots and least squares regression lines showing correlations between levels of HDL N-Tyr and HDL Cl-Tyr
oxidation, MPO and HDL Cl-Tyr oxidation, MPO and HDL N-Tyr oxidation, and MPO and chlorination levels at Tyr192 (HDL 3-CLY 192) within
Apo A-I from SLE patients.
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Figure 2. Neutrophil extracellular trap (NET)–derived myeloperoxidase (MPO), nitric oxide synthase (NOS), and NADPH oxidase (NOX) modify
human high-density lipoprotein (HDL). Immunofluorescence staining and immunoblotting were used to identify possible enzymatic sources of HDL
nitration. A, Detection of NOX subunits, p22 and p47, and 2 NOS isoforms, endothelial cell NOS (eNOS) and inducible NOS (iNOS), in human
NETs. Control neutrophil NETs and lupus low-density granulocyte (LDG) NETs were added to control, nonoxidized HDL. Original magnifica-
tion  63. B and C, Resulting levels of MPO-specific 3-chlorotyrosine (B), and reactive nitrogen species–mediated 3-nitrotyrosine (C) oxidation, as
quantified by mass spectrometry. L-NG-monomethyl-L-arginine (L-NMMA), diphenyleneiodonium (DPI), and 3-amino-1,2,4-triazole (3-AT) were
added to block NOS, NOX, and MPO activity, respectively. The peptidylarginine deiminase inhibitor Cl-amidine (Cl-Am) was added to LDGs to
block spontaneous NETosis. For control neutrophils, the absence of phorbol myristate acetate (PMA) stimulation was used as a negative control
for NETosis. Bars show the mean  SEM (n  6 subjects per group).   P  0.007;   P  0.0002;   P  0.0001. NS  not significant.
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115, 100, 29, and 18 in SLE (Figure 1C). Taken together,
these data suggest that regiospecific modifications to
HDL by MPO and RNS, specifically at Tyr18, Tyr115, and
Tyr192, may be of particular interest in the context of
SLE-associated CVD.
When we examined correlations between levels
of N-Tyr and Cl-Tyr in SLE HDL, they positively
correlated with each other (Figure 1D) (r  0.39, P 
0.0019), suggesting that these oxidative modifications
are generated at similar sites. While levels of Cl-Tyr
significantly correlated with plasma MPO levels (Figure
1D) (r  0.36, P  0.0049), there was no significant
correlation between N-Tyr and MPO levels (Figure 1D)
(r  0.03, P  0.83). This suggests that the RNS leading
to HDL nitration are not primarily derived from MPO,
but from another oxidative source. While tyrosines 115
and 18 displayed the highest levels of oxidation in lupus,
Cl-Tyr 192 showed the most significant positive correla-
tion with plasma MPO levels (Figure 1D). Overall, these
results support the notion that in SLE, RNS- and
MPO-derived oxidants modify HDL, thereby impairing
lipoprotein function.
Oxidation in total plasma proteins was also de-
termined (Table 2). Similar trends were observed as for
HDL. Median plasma N-Tyr levels were 8.8-fold higher
in lupus patients than in controls (286.0 versus 32.5
moles/mole Tyr; P  0.0001) and median plasma
Cl-Tyr levels were 40.6-fold higher in lupus patients than
in controls (33.3 versus 0.82 moles/mole Tyr; P 
0.0001), which persisted after adjustment (Table 2;
values in table are natural log transformed). As ex-
pected, the levels of plasma and HDL Cl-Tyr in SLE
trended toward a negative correlation with CEC per-
centage, while HDL N-Tyr levels showed no significant
association (data not shown) (14). Overall, this profile of
enhanced HDL and total plasma protein oxidation is
consistent with an environment of increased oxidative
stress and impaired CEC in SLE.
Promotion of HDL oxidation in vitro by NET-
derived MPO, NOX, and NOS. Since levels of RNS- and
MPO-derived oxidative modifications are markedly ele-
vated in lupus and correlate with functional impairment
of CEC, we attempted to identify the putative sources of
enhanced RNS and MPO activity in SLE. MPO HDL
oxidation is classically attributed to plaque macrophages
(12,24). Another possible source is peripheral blood
MPO, which has been reported to be enhanced in SLE
(21) and which we were able to confirm (Tables 1 and 2).
Since a subset of neutrophils in the peripheral blood of
lupus patients (LDGs) has a significantly enhanced
capacity to form NETs, a source of externalized NOX
and MPO, we examined if the NETs could induce HDL
oxidation (4,27,33). Additionally, because we found that
MPO levels did not correlate with N-Tyr HDL levels
(Figure 1D), we examined if an alternative producer of
RNS (NOS and NOX formation of ONOO) could be
present in NETs and serve as a source of HDL nitration.
MPO (not shown), NOX, and NOS were all
detected on both control and LDG NETs by fluores-
cence microscopy and immunoblotting (Figure 2A).
Next, we exposed native HDL to NETs isolated from
PMA-stimulated control neutrophils or spontaneously
by lupus LDGs, in the absence or presence of MPO,
NOX, and NOS inhibitors (3-AT, DPI, and L-NMMA,
respectively) and examined the HDL oxidation profile.
As shown in Figures 2B and C, NETs from both lupus
LDGs and control neutrophils significantly enhanced
HDL oxidation. HOCl, which is synthesized by MPO
downstream of NOX activity, is the major source of
HDL chlorination in humans. When netting control
neutrophils and lupus LDGs were treated with 3-AT and
DPI to block MPO and NOX activity, respectively, HDL
Cl-Tyr oxidation was abrogated (Figure 2B). These
results support the hypothesis that MPO and NOX
externalized on NETs can induce Cl-Tyr HDL oxidation
in the periphery.
Because both NOS and MPO are capable of
producing the RNS required for HDL nitration, we used
a KRPG solution with no added nitrite to examine the
role of NOS alone in N-Tyr oxidation. Under these
conditions, only NOS could generate the NO• required
for ONOO formation that could lead to HDL nitra-
tion. MPO, under these conditions, could not be the
source of RNS. Indeed, the MPO inhibitor 3-AT was
ineffective at blocking HDL nitration, while the NOS
inhibitor L-NMMA significantly abrogated HDL N-Tyr
oxidation for both LDGs and control neutrophils (Fig-
ure 2C). These results suggest that NET-bound NOS is
a source of the RNS causing HDL nitration, and may
explain why the levels of MPO did not correlate with the
levels of N-Tyr–oxidized HDL in SLE.
Blockade of NET formation in vitro by CQ. We
determined the effect of physiologically relevant concen-
trations of CQ (250 ng/ml) on NET formation (17). CQ
significantly inhibited NET formation in control neutro-
phils and lupus LDGs (Figures 3A–C). To assess if CQ
modified MPO, NOS, and NOX activity, neutrophils
were homogenized, treated with CQ, and incubated with
HDL. CQ did not significantly block HDL Cl-Tyr or
N-Tyr oxidation in lupus LDGs or control neutrophils
(data not shown). Therefore, the inhibitory effects of
CQ on NET formation do not occur by inhibition of
oxidative enzyme activity.
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NET-derived NOS and NOX are sources of HDL
oxidation in murine systems. While present in murine
NETs, MPO is not associated with murine atherosclero-
sis (24,47). Lupus-prone NZM mice display striking
elevations of N-Tyr HDL oxidation, but not Cl-Tyr HDL
oxidation, when compared to control mice (5), possibly
because murine leukocytes contain less MPO, the sole
known source of Cl-Tyr oxidation, than human leuko-
Figure 3. Chloroquine (CQ) abrogates NET formation. A, Control neutrophil and lupus LDG fluorescence. Control neutrophils or lupus LDGs
were purified from whole blood, treated with or without CQ, and assessed for DNA externalization via Sytox assay. B and C, Quantification of NET
production (B) and MPO, iNOS, and p22 externalization on the NETs (C), determined by immunofluorescence staining of cells treated with or
without CQ. Original magnification  63 in C. Bars in A and B show the mean  SEM (n  5 subjects per group).   P  0.01;   P  0.0001;
  P  0.0001. LPS  lipopolysaccharide (see Figure 2 for other definitions).
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cytes (12,24,47). We therefore examined if NOX and
NOS were present in murine NETs and could produce
RNS to form N-Tyr–oxidized HDL (26,33). We identi-
fied NOS and NOX machinery present in PMA-induced
murine NETs (Figure 4A). To verify that these NET-
bound enzymes could cause HDL oxidation, we exposed
native HDL from non–lupus-prone BALB/c mice to
proteins purified from digested NETs from NZM or
BALB/c mice in the absence or presence of MPO, NOX,
and NOS inhibitors (3-AT, DPI, and L-NMMA, respec-
tively) and examined HDL oxidation profiles
(26,27,32,33,44,45). Consistent with our previous obser-
vations, we found no significant Cl-Tyr–oxidized HDL
patterns after HDL incubation with murine NETs (Fig-
ure 4B) (5). However, a significant oxidation pattern for
N-Tyr–oxidized HDL was observed (Figure 4C). While
experiments were performed in nitrite-containing media
so that either NOS or MPO could potentially promote
HDL nitration, only DPI and L-NMMA significantly
blocked NET-induced N-Tyr HDL oxidation. These
results support the idea that MPO is less active in mice
and that NOX and NOS are the primary sources of the
oxidative species required for HDL nitration in murine
systems.
Finally, to verify that NETs are an important
source of HDL oxidation in the periphery, we inhibited
NET formation in NZM mice in vivo and examined their
oxidative profile. NZM mice received the PAD inhibitor
Cl-amidine daily for 14 weeks, since PAD activity is
necessary for NET formation (6,34). Cl-amidine–treated
mice displayed significantly decreased N-Tyr content in
HDL, but not total plasma, when compared to vehicle-
treated mice (Figure 4D). These results indicate that in
vivo inhibition of NET formation in lupus-prone mice
decreases HDL oxidation.
DISCUSSION
Part of the high risk of CVD observed in SLE
may be related to increased levels and activity of oxida-
tive enzymes that transform HDL into a dysfunctional
proatherogenic lipoprotein (1,3,21). We found that lu-
pus plasma exhibited impaired CEC, and SLE patients
had significantly increased plasma MPO levels and
highly Cl-Tyr– and N-Tyr–oxidized plasma proteins,
including HDL Apo A-I. HDL nitration did not corre-
late with MPO levels, indicating an alternate source of
RNS. However, Cl-Tyr– and N-Tyr–oxidized HDL levels
correlated with each other, suggesting that both modifi-
cations occur at similar sites in the vasculature, though
not through the same enzyme. Because of the link
between SLE and enhanced NET formation, we hypoth-
esized that the enzymatic sources of the proatherogenic
oxidized HDL were derived from active NOS, MPO, and
NOX present in NETs. Indeed, previous studies suggest
that these oxidative enzymes may have enhanced activity
while bound on NETs (26). All 3 oxidative enzymes were
detected and functional in NETs, as demonstrated when
mass spectrometric analysis performed on HDL incu-
bated with NETs revealed oxidative modifications (chlo-
rination and nitration). Use of specific inhibitors for
each of these enzymes reduced this oxidation, further
confirming functional activity of these NET enzymes.
Finally, we demonstrated that pharmacologic in vivo
NET inhibition potently decreased levels of proinflam-
matory N-Tyr–oxidized HDL in lupus-prone mice.
These observations suggest a crucial role for NETs in the
transformation of HDL into its proinflammatory form.
The connection between NET oxidation of HDL
and plasma proteins is particularly interesting and novel
in the context of chronic inflammatory conditions such
as SLE, RA, and vasculitis (8,28). Since lupus patients
exhibit both accelerated NET formation and impaired
NET degradation, these structures represent a potent
and long-term source of externalized oxidative material
(4,29,30). Most of the literature to date has focused on
atherosclerotic plaque macrophages as sources of MPO-
driven HDL oxidation, yet circulating neutrophils con-
tain higher levels of MPO than tissue-resident macro-
phages (12,24), and neutrophils and NETs are present
around thrombotic and atheroma plaques (35,38,39,48).
The high concentration of MPO in NETs may even
specifically attract HDL for oxidation. Consistent with
previous reports, we found that Cl-Tyr levels in HDL are
higher than in circulating plasma proteins, suggesting
specific targeting of HDL (8,18). While other investiga-
tors have demonstrated that neutrophils can cause pro-
tein oxidation, our observations are the first to specifi-
cally implicate active MPO, NOX, and NOS in NETs as
sources of HDL oxidation (44), and to demonstrate
NOS in NETs. Which NOS isoform is required for
NET-derived HDL oxidation is not yet clear. Nonethe-
less, NOS activity in NETs and its association with HDL
nitration opens potential avenues for CVD therapies.
To our knowledge, this is the first study to show
that physiologic concentrations of antimalarials signifi-
cantly inhibit NET formation in vitro. Previous evidence
suggested that antimalarials are effective in SLE through
modulation of Toll-like receptors and antigen presenta-
tion (49,50). We now describe an additional putative
protective role of antimalarials in autoimmunity through
modulation of NET formation. While use of antimalar-
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Figure 4. NET-derived NOS and NOX induce HDL oxidation in mice, while NET inhibition decreases HDL oxidation in vivo. Immunofluorescence
staining and immunoblotting were used to identify possible enzymatic sources of HDL nitration. A, Detection of NOX subunits, p22 and p47, and
2 NOS isoforms, eNOS and iNOS, in murine NETs. NETs from control BALB/c mice and NZM2328 (NZM) mice with lupus were added to control,
nonoxidized murine HDL. Original magnification  63. B, Resulting levels of MPO-specific 3-chlorotyrosine oxidation in the absence or presence
of isolated NETs, as quantified by mass spectrometry. Bars show the mean  SEM (n  4 mice per group). C, Resulting levels of NOS- and
NOX-mediated 3-nitrotyrosine oxidation, as quantified by mass spectrometry. L-NMMA, DPI, and 3-AT were added to block NOS, NOX, and MPO
activity, respectively. The absence of PMA stimulation was used as a negative control for NET formation. Comparisons were made within the same
mouse strain. Bars show the mean  SEM (n  8 mice per group). D, Levels of plasma and HDL 3-nitrotyrosine content in 26-week-old NZM mice
that had received daily injections of phosphate buffered saline (vehicle; n  8) or Cl-amide (n  8) for 14 weeks. Symbols represent individual mice;
horizontal lines and error bars show the median and SEM.   P  0.01;   P  0.0001. See Figure 2 for other definitions.
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ials associated only with plasma N-Tyr oxidation, the
small sample size might have limited observing an effect.
This should be further explored in future studies.
The current study has some limitations. The
effects on CEC reduction of 15% might appear modest,
but we previously reported similar results in RA (8).
Recent clinical studies have demonstrated smaller,
though statistically significant, percent reductions in
CEC with larger CVD and psoriasis cohort sample sizes
(17,43). Our results therefore are consistent with the
findings of these studies and even show a greater
reduction in CEC than in traditional CVD. Further,
while we focused on total HDL in this study, HDL
subpopulations might be different in lupus patients
compared to control subjects and might account for
altered susceptibility.
The proatherogenic effects of NETs include di-
rect vascular cytotoxicity, activation of macrophage in-
flammasomes, and induction of procoagulant pathways
(1,28–31,37,48). Overall, this study suggests an addi-
tional proatherogenic mechanism by which NET-derived
MPO/NOX- and NOS/NOX-generated oxidative species
may generate dysfunctional HDL in SLE. HDL oxida-
tion in SLE may take place in the periphery rather than
the vascular wall (1,31). Given its small particle size and
active circulation during cholesterol efflux, HDL is,
conceivably, more readily trapped by NETs in the blood
vessel lumen, endothelium, or sites of inflammation,
rather than in subendothelial atherosclerotic lesions
(17,35,36). NET-mediated modification of HDL may
lead to a dysfunctional lipoprotein, impairing CEC and
promoting proinflammatory responses in blood vessels
and the periphery.
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